Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Angiotensin Ii Acetate

FDA-approved product (solution, intravenous), marketed as Angiotensin Ll Acetate, Giapreza.

Registered studies
10
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Angiotensin Ii Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypotension
  • Septic shock
  • Shock

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cardiac stimulants
FDA pharmacologic class
Vasoconstrictor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Angiotensin Ii Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Angiotensin Ii Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

    NCT06482853 · start 2025-01-23

    Registered record
    Registry ID
    NCT06482853
    Conditions
    Obesity; Hypertension
    Interventions
    Angiotensin-(1-7); Saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-01-23
    Completion
    2029-03
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Hypertension
    InterventionAngiotensin-(1-7); Saline
    PhaseEarly phase 1
    Registry statusRecruiting

  • Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

    NCT06282965 · start 2024-05-28

    Registered record
    Registry ID
    NCT06282965
    Conditions
    Traumatic Brain Injury
    Interventions
    Angiotensin (1-7); Sterile saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-05-28
    Completion
    2027-09
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraumatic Brain Injury
    InterventionAngiotensin (1-7); Sterile saline
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

    NCT05709444 · start 2022-12-26

    Registered record
    Registry ID
    NCT05709444
    Conditions
    Kidney Disease
    Interventions
    Bremelanotide; RAAS inhibition therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-12-26
    Completion
    2024-04-26
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Disease
    InterventionBremelanotide; RAAS inhibition therapy
    PhasePhase 2
    Registry statusCompleted

  • Angiotensin-(1-7) Cardiovascular Effects in Aging

    NCT05301192 · start 2022-12-09

    Registered record
    Registry ID
    NCT05301192
    Conditions
    Aging
    Interventions
    Angiotensin-(1-7); Saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2022-12-09
    Completion
    2026-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging
    InterventionAngiotensin-(1-7); Saline
    PhaseEarly phase 1
    Registry statusRecruiting

  • Angiotensin-(1-7) and Energy Expenditure in Human Obesity

    NCT03777215 · start 2019-09-26

    Registered record
    Registry ID
    NCT03777215
    Conditions
    Obesity
    Interventions
    Angiotensin-(1-7); Saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2019-09-26
    Completion
    2026-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionAngiotensin-(1-7); Saline
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • Angiotensin 1-7 in Obesity Hypertension

    NCT03604289 · start 2019-04-01

    Registered record
    Registry ID
    NCT03604289
    Conditions
    Obesity; Hypertension
    Interventions
    Angiotensin-(1-7); Saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2019-04-01
    Completion
    2023-06-03
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Hypertension
    InterventionAngiotensin-(1-7); Saline
    PhaseEarly phase 1
    Registry statusTerminated

  • Angiotensin-(1-7) in Peripheral Arterial Disease

    NCT03240068 · start 2017-09-01

    Registered record
    Registry ID
    NCT03240068
    Conditions
    Peripheral Arterial Disease
    Interventions
    Angiotensin 1-7; Saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2017-09-01
    Completion
    2020-03-09
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Arterial Disease
    InterventionAngiotensin 1-7; Saline
    PhaseEarly phase 1
    Registry statusTerminated

  • Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

    NCT02591173 · start 2016-02

    Registered record
    Registry ID
    NCT02591173
    Conditions
    Autonomic Nervous System Disorders; Pure Autonomic Failure; Shy-Drager Syndrome; Orthostatic Hypotension, Dysautonomic
    Interventions
    Angiotensin-(1-7); Saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2016-02
    Completion
    2020-07
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Nervous System Disorders; Pure Autonomic Failure; Shy-Drager Syndrome; Orthostatic Hypotension, Dysautonomic
    InterventionAngiotensin-(1-7); Saline
    PhaseEarly phase 1
    Registry statusTerminated

  • Metabolic Effects of Angiotensin-(1-7)

    NCT02646475 · start 2016-02

    Registered record
    Registry ID
    NCT02646475
    Conditions
    Obesity; Insulin Resistance; Hypertension; Metabolic Cardiovascular Syndrome
    Interventions
    Angiotensin-(1-7); Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2016-02
    Completion
    2029-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Insulin Resistance; Hypertension; Metabolic Cardiovascular Syndrome
    InterventionAngiotensin-(1-7); Saline
    PhasePhase 1
    Registry statusRecruiting

  • Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

    NCT01393782 · start 2011-07

    Registered record
    Registry ID
    NCT01393782
    Conditions
    Septic Shock
    Interventions
    Angiotensin II
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionAngiotensin II
    PhasePhase 1
    Registry statusCompleted